Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 4/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29815064 | 1.00 | NAPRT (0.47) | NAPRTL3MBTL1POLBMAPTRAB9A | |
| SCHEMBL29525674 | 0.85 | KCNQ3 (0.41) | L3MBTL1MAPTRAB9AKCNQ3KCNQ2 | |
| SCHEMBL416586 | 0.85 | KCNQ3 (0.41) | L3MBTL1MAPTRAB9AKCNQ3KCNQ2 | |
| SCHEMBL6726735 | 0.85 | KCNQ3 (0.41) | L3MBTL1MAPTRAB9AKCNQ3KCNQ2 | |
| SCHEMBL19816909 | 0.84 | MAPK1 (0.53) | L3MBTL1POLBMAPTRAB9ANPC1 | |
| SCHEMBL6726742 | 0.84 | KMT2A (0.50) | L3MBTL1MAPTKCNQ3KCNQ2 | |
| SCHEMBL19360803 | 0.82 | MAPK1 (0.37) | L3MBTL1MAPTRAB9ALMNANPC1 | |
| SCHEMBL17544977 | 0.81 | ALOX5AP (0.41) | L3MBTL1MAPTSMN1; SMN2LMNA | |
| SCHEMBL23812432 | 0.80 | HCAR3 (0.53) | L3MBTL1MAPTRAB9ANPC1 | |
| SCHEMBL16305781 | 0.80 | MGLL (0.42) | L3MBTL1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115744-A1 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | LUMINA PHARMACEUTICALS INC. | 2024-04-11 | — | — | US | disclosed |
| US-11542234-B2 | 2-alkoxy-6-[18F]fluoronicotinoyl substituted lys-c(O)-glu derivatives as efficient probes for imaging of PSMA expressing tissues | UNIVERSITÄT ZU KÖLN (DE) | 2023-01-03 | — | — | US | disclosed |
| EP-4048324-A1 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | Collagen Medical, LLC (US) | 2022-08-31 | — | — | EP | disclosed |
| CN-114945388-A | Fibrin-binding compounds for imaging and therapy | 胶原蛋白医疗有限责任公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220088229-A1 | PSMA-BINDING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | disclosed |
| EP-3353152-B1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-09-15 | — | — | EP | disclosed |
| US-20210252174-A1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-08-19 | — | — | US | disclosed |
| WO-2021081430-A1 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | Collagen Medical, LLC (US) | 2021-04-29 | — | — | WO | disclosed |
| US-20210032206-A1 | 2-Alkoxy-6-[18F]fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues | UNIVERSITÄT ZU KÖLN (DE) | 2021-02-04 | — | — | US | disclosed |
| US-10869942-B2 | Method | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2020-12-22 | — | — | US | disclosed |
| US-8778305-B2 | PSMA-binding agents and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-8530620-B2 | Radiolabelling reagents and methods | GE HEALTHCARE LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-8530620-B2 | Radiolabelling reagents and methods | GE HEALTHCARE LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| EP-2414333-B1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LTD (GB) | 2013-02-13 | — | — | EP | disclosed |
| CN-102356069-A | Radiolabelling reagents and methods | GE HEALTHCARE LTD | 2012-02-15 | — | — | CN | disclosed |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20110142760-A1 | PSMA-BINDING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110142760-A1 | PSMA-BINDING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010114723-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142760-A1 | PSMA-BINDING AGENTS AND USES THEREOF | KLK3, FOLH1, DNPEP | NAPRT 2556/4885L3MBTL1 2098/4885POLB 2674/4885 |
| US-20240115744-A1 | FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT | FGB, F13B, F2 | NAPRT 3986/4885L3MBTL1 1814/4885POLB 3494/4885 |
| US-20220088229-A1 | PSMA-BINDING AGENTS AND USES THEREOF | KLK3, FOLH1, DNPEP | NAPRT 2556/4885L3MBTL1 2098/4885POLB 2674/4885 |
| US-10869942-B2 | Method | MPI, DUT, NT5E | NAPRT 269/4885L3MBTL1 4154/4885POLB 2188/4885 |
| US-20210032206-A1 | 2-Alkoxy-6-[18F]fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues | FGB, GLUL, PYGB | NAPRT 2005/4885L3MBTL1 1405/4885POLB 488/4885 |
| US-20210252174-A1 | METHOD | MPI, DUT, NT5E | NAPRT 269/4885L3MBTL1 4154/4885POLB 2188/4885 |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | ANPEP, DNPEP, QRFPR | NAPRT 1259/4885L3MBTL1 2812/4885POLB 2199/4885 |
| US-11542234-B2 | 2-alkoxy-6-[18F]fluoronicotinoyl substituted lys-c(O)-glu derivatives as efficient probes for imaging of PSMA expressing tissues | FGB, GLUL, PYGB | NAPRT 2005/4885L3MBTL1 1405/4885POLB 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.